Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-6129 in R/R Systemic AL Amyloidosis
NCT05692908Phase 1Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 1, open-label, single-arm trial of STI-6129 in amyloid light chain amyloidosis, sponsored by Sorrento Therapeutics. Primary endpoint: Safety of STI-6129. Planned start Sep 2023; status: withdrawn.
02
Drugs
STI-6129
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT05692908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05692908.